Citation Impact
Citing Papers
Endoscopic improvement of mucosal lesions in patients with moderate to severe ileocolonic Crohn's disease following treatment with certolizumab pegol
2012
Secukinumab, a human anti-IL-17A monoclonal antibody, for moderate to severe Crohn's disease: unexpected results of a randomised, double-blind placebo-controlled trial
2012 Standout
Autologous nonmyeloablative hematopoietic stem cell transplantation in patients with severe anti-TNF refractory Crohn disease: long-term follow-up
2010
Molecular-phylogenetic characterization of microbial community imbalances in human inflammatory bowel diseases
2007 Standout
Mucosal healing in inflammatory bowel diseases: a systematic review
2012 Standout
Update on prevention, diagnosis, and treatment of chronic hepatitis B: AASLD 2018 hepatitis B guidance
2018 Standout
Presence of papillomavirus sequences in condylomatous lesions of the mamillae and in invasive carcinoma of the breast
2004 StandoutNobel
Rifaximin-Extended Intestinal Release Induces Remission in Patients With Moderately Active Crohn's Disease
2011
Food-grade TiO2 impairs intestinal and systemic immune homeostasis, initiates preneoplastic lesions and promotes aberrant crypt development in the rat colon
2017 Standout
Cytokines in inflammatory bowel disease
2014 Standout
Immunotherapy in Inflammatory Bowel Disease
2012
Atopic Dermatitis
2008 Standout
Fecal Calprotectin More Accurately Reflects Endoscopic Activity of Ulcerative Colitis than the Lichtiger Index, C-reactive Protein, Platelets, Hemoglobin, and Blood Leukocytes
2013
Comparative Effectiveness of Immunosuppressants and Biologics for Inducing and Maintaining Remission in Crohn's Disease: A Network Meta-analysis
2014
Conventional Medical Management of Inflammatory Bowel Disease
2011
Vedolizumab as Induction and Maintenance Therapy for Ulcerative Colitis
2013 Standout
Diagnosis and management of fistulizing Crohn's disease
2009
The multitude and diversity of environmental carcinogens
2007 StandoutNobel
The mucosal addressin cell adhesion molecule antibody PF-00547,659 in ulcerative colitis: a randomised study
2011
Toward a Personalized Medicine Approach to the Management of Inflammatory Bowel Disease
2014
Review article: minimizing tuberculosis during anti‐tumour necrosis factor‐alpha treatment of inflammatory bowel disease
2007
Ulcerative Colitis
2011 Standout
Clinical trial: benefits and risks of immunomodulators and maintenance infliximab for IBD‐subgroup analyses across four randomized trials
2009
Adalimumab safety in global clinical trials of patients with Crohnʼs disease
2009
Atopic dermatitis
2015 Standout
Autologous bone marrow-derived mesenchymal stromal cells in the treatment of fistulising Crohn's disease
2011 Standout
Biological therapies in Crohn’s disease: are they cost-effective? A critical appraisal of model-based analyses
2014
The Impact of PEGylation on Biological Therapies
2008
Ustekinumab Induction and Maintenance Therapy in Refractory Crohn's Disease
2012
Ulcerative Colitis Practice Guidelines in Adults (Update): American College of Gastroenterology, Practice Parameters Committee
2004 Standout
Crohn's disease
2012 Standout
Placental Transfer of Anti–Tumor Necrosis Factor Agents in Pregnant Patients With Inflammatory Bowel Disease
2012
Itching for Insight
2009 StandoutNobel
How Rapidly Should Remission Be Achieved?
2010
Edible ginger-derived nanoparticles: A novel therapeutic approach for the prevention and treatment of inflammatory bowel disease and colitis-associated cancer
2016 Standout
Hepatitis B virus infection and immunosuppressive therapy in patients with inflammatory bowel disease
2010
Psoriasis
2021 Standout
The natural history of corticosteroid therapy for inflammatory bowel disease: A population-based study
2001 Standout
Food allergy: Epidemiology, pathogenesis, diagnosis, and treatment
2014 Standout
Opportunistic Infections With Anti-Tumor Necrosis Factor-α Therapy in Inflammatory Bowel Disease: Meta-Analysis of Randomized Controlled Trials
2013
Psoriasis: Which therapy for which patient
2018
Optimizing the safety of biologic therapy for IBD
2010
Inflammatory Bowel Disease
2009 Standout
The role of DMARDs in reducing the immunogenicity of TNF inhibitors in chronic inflammatory diseases
2013
Cytokines and chemokines: At the crossroads of cell signalling and inflammatory disease
2014 Standout
IL-6 as a keystone cytokine in health and disease
2015 Standout
Therapeutic antibodies for autoimmunity and inflammation
2010
Human papillomavirus 16 in breast cancer of women treated for high grade cervical intraepithelial neoplasia (CIN III).
1999
Antibody therapy of cancer
2012 Standout
A Randomized Trial of Ustekinumab, a Human Interleukin-12/23 Monoclonal Antibody, in Patients With Moderate-to-Severe Crohn's Disease
2008
Pathophysiology and therapy of pruritus in allergic and atopic diseases
2010
Biological Therapies for Inflammatory Bowel Diseases
2009
Inflammation and Colon Cancer
2010 Standout
Ulcerative colitis
2012 Standout
Current status of monoclonal antibody therapy for the treatment of inflammatory bowel disease
2010
Current status of monoclonal antibody therapy for the treatment of inflammatory bowel disease: an update
2012
PEGylation as a strategy for improving nanoparticle-based drug and gene delivery
2015 Standout
Interleukin-17 and Type 17 Helper T Cells
2009 Standout
Crohn's disease: beyond antagonists of tumour necrosis factor
2008
STRIDE-II: An Update on the Selecting Therapeutic Targets in Inflammatory Bowel Disease (STRIDE) Initiative of the International Organization for the Study of IBD (IOIBD): Determining Therapeutic Goals for Treat-to-Target strategies in IBD
2021 Standout
Crohn's disease
2016 Standout
Review article: remission rates achievable by current therapies for inflammatory bowel disease
2011
Targeting the IL-6/JAK/STAT3 signalling axis in cancer
2018 Standout
Designing hydrogels for controlled drug delivery
2016 Standout
Ulcerative colitis
2016 Standout
The role of histamine H1 and H4 receptors in allergic inflammation: the search for new antihistamines
2008
The second European evidence-based Consensus on the diagnosis and management of Crohn's disease: Current management
2010
Relationship of C-Reactive Protein With Clinical Response After Therapy With Ustekinumab in Crohn's Disease
2009
Site-specific chemical protein conjugation using genetically encoded aldehyde tags
2012 StandoutNobel
Frontiers in pruritus research: scratching the brain for more effective itch therapy
2006
Ulcerative colitis
2020 Standout
Nanoparticle-Based Medicines: A Review of FDA-Approved Materials and Clinical Trials to Date
2016 Standout
Transient Receptor Potential Cation Channels in Disease
2007 Standout
Polymeric micelles in drug delivery: An insight of the techniques for their characterization and assessment in biorelevant conditions
2021 Standout
Maintenance of Remission Among Patients With Crohn's Disease on Antimetabolite Therapy After Infliximab Therapy Is Stopped
2011
Clinical Utility of Measuring Infliximab and Human Anti-Chimeric Antibody Concentrations in Patients With Inflammatory Bowel Disease
2010
Protein adsorption is required for stealth effect of poly(ethylene glycol)- and poly(phosphoester)-coated nanocarriers
2016 Standout
First-line therapy in adult Crohn's disease: who should receive anti-TNF agents?
2013
The global burden of IBD: from 2015 to 2025
2015 Standout
Infliximab, Azathioprine, or Combination Therapy for Crohn's Disease
2010 Standout
Biologic agents for IBD: practical insights
2015
Vedolizumab as Induction and Maintenance Therapy for Crohn's Disease
2013 Standout
Management of Crohn's Disease in Adults
2009 Standout
Towards personalized care in IBD
2013
Adalimumab Induces and Maintains Clinical Remission in Patients With Moderate-to-Severe Ulcerative Colitis
2011 Standout
A global consensus on the classification, diagnosis and multidisciplinary treatment of perianal fistulising Crohn's disease
2014
An Evidence-Based Systematic Review on Medical Therapies for Inflammatory Bowel Disease
2011
Systematic review: monotherapy with antitumour necrosis factor α agents versus combination therapy with an immunosuppressive for IBD
2014
Tofacitinib for induction and maintenance therapy of Crohn's disease: results of two phase IIb randomised placebo-controlled trials
2017
Recent developments in the treatment of inflammatory bowel disease
2013
From Stealthy Polymersomes and Filomicelles to “Self” Peptide-Nanoparticles for Cancer Therapy
2014
Endpoints for clinical trials evaluating disease modification and structural damage in adults with Crohnʼs disease
2009
Atopic dermatitis: A practice parameter update 2012
2013
[Crohn's disease].
1960
Investigational drugs in phase I and phase II clinical trials targeting interleukin 23 (IL23) for the treatment of Crohn’s disease
2018
A retrospective analysis: the development of patient reported outcome measures for the assessment of Crohn's disease activity
2014
Sensitive Quantification of PEGylated Compounds by Second-Generation Anti-Poly(ethylene glycol) Monoclonal Antibodies
2010
FDA-approved poly(ethylene glycol)–protein conjugate drugs
2011
Budesonide for induction of remission in Crohn's disease
2015
Efficacy and Safety of Tumor Necrosis Factor Antagonists in Crohn's Disease: Meta-Analysis of Placebo-Controlled Trials
2008
Tissue-specific contributions of Tmem79 to atopic dermatitis and mast cell-mediated histaminergic itch
2018 StandoutNobel
Vedolizumab provides clinical benefit over 1 year in patients with active inflammatory bowel disease - a prospective multicenter observational study
2016
Role of the Methoxy Group in Immune Responses to mPEG-Protein Conjugates
2012
Works of Ralph Bloomfield being referenced
Increased Response and Remission Rates in Short-Duration Crohn's Disease With Subcutaneous Certolizumab Pegol: An Analysis of PRECiSE 2 Randomized Maintenance Trial Data
2010
Clinical trial: impact of prior infliximab therapy on the clinical response to certolizumab pegol maintenance therapy for Crohn’s disease
2010
Continuous Therapy With Certolizumab Pegol Maintains Remission of Patients With Crohn's Disease for up to 18 Months
2010
Maintenance Therapy with Certolizumab Pegol for Crohn's Disease
2007
Certolizumab Pegol for Active Crohn's Disease: A Placebo-Controlled, Randomized Trial
2011
Randomised clinical trial: certolizumab pegol for fistulas in Crohn’s disease - subgroup results from a placebo-controlled study
2010
Certolizumab Pegol for the Treatment of Crohn's Disease
2007
Reinduction With Certolizumab Pegol in Patients With Relapsed Crohn's Disease: Results From the PRECiSE 4 Study
2010
Chlorpheniramine Is No More Effective than Placebo in Relieving the Symptoms of Childhood Atopic Dermatitis with a Nocturnal Itching and Scratching Component
2002
Induction Therapy with Certolizumab Pegol in Patients with Moderate to Severe Crohnʼs Disease: A Placebo-Controlled Trial
2010
Human papillomavirus type 16 DNA in anal cancers from six different countries.
1991